Stereotaxis announced the first patients have been treated utilizing Abbott’s EnSite X EP System with Stereotaxis’ Robotic Magnetic Navigation System. The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery. The integration of these technologies was announced at Heart Rhythm 2023. The first integrated procedures were successfully conducted by Dr. Sing-Chien Yap and Dr. Tamas Szili-Torok at Erasmus Medical Center in Rotterdam, The Netherlands, and by Dr. Burkhard Hugl at Marienhaus St. Elisabeth Hospital in Neuwied, Germany.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on STXS:
- Stereotaxis and Abbott Combine Technologies in First Integrated Procedures to Treat Arrhythmia Patients
- Stereotaxis to Report Second Quarter 2023 Financial Results on August 10, 2023
- Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter
- Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference
- Advocate Christ Medical Center Extends Leadership in Heart Care with Adoption of Genesis Robotic Technology